TheraRadar
Data updated: May 26, 2026

LEVOCARNITINE

Metabolic Approved 2001-03-29

LEVOCARNITINE is indicated for the treatment of Carnitine Deficiency; Reye-like Encephalopathy; Hypoglycemia; Cardiomyopathy; Inborn Error of Metabolism.

Source: FDA Label • AM REGENT
9
Indications
--
Phase 3 Trials
25
Years on Market

Details

Status
Prescription
First Approved
2001-03-29
Routes
INJECTION, ORAL
Dosage Forms
INJECTABLE, TABLET, SOLUTION

LEVOCARNITINE Approval History

2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
20 FDA actions from 2001 to 2025
Jun 2025 ORIGINAL
Update
Jul 2024 SUPPL
Label · Labeling
Dec 2023 SUPPL
Mfg · Manufacturing (CMC)

What LEVOCARNITINE Treats

5 indications

LEVOCARNITINE is approved for 5 conditions since its original approval in 2001. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Carnitine Deficiency
  • Reye-like Encephalopathy
  • Hypoglycemia
  • Cardiomyopathy
  • Inborn Error of Metabolism
Source: FDA Label

LEVOCARNITINE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to LEVOCARNITINE

3 of 10

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CARNITOR
LEVOCARNITINE
5 shared
LEADIANT BIOSCI INC
Shared indications:
Carnitine DeficiencyReye-like EncephalopathyHypoglycemia +2 more
CARNITOR SF
LEVOCARNITINE
5 shared
LEADIANT BIOSCI INC
Shared indications:
Carnitine DeficiencyReye-like EncephalopathyHypoglycemia +2 more
LEVOCARNITINE SF
LEVOCARNITINE
5 shared
NOVITIUM PHARMA
Shared indications:
Carnitine DeficiencyReye-like EncephalopathyHypoglycemia +2 more
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT03953703 irb200020 Ph 2 completed Levocarnitine for Dry Eye in Sjogren's Syndrome
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LEVOCARNITINE FDA Label Details

Indications & Usage

FDA Label (PDF)

LEVOCARNITINE is indicated for the treatment of Carnitine Deficiency; Reye-like Encephalopathy; Hypoglycemia; Cardiomyopathy; Inborn Error of Metabolism.

Looking for the branded version?

CARNITOR

Full clinical data, patents, trials, and competitive landscape for levocarnitine.

See CARNITOR

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.